BENEVOLENTBIO
BenevolentBio is responsible for applying the company’s technology in the human health and bioscience sectors. It is a subsidiary of BenevolentAI. Currently the company is focused on the disease areas of inflammation, neurodegeneration (e.g. Parkinson’s, Alzheimer’s), orphan diseases (e.g. Amyotrophic Lateral Sclerosis - ‘ALS’) and rare cancers. However, given the scope of BenevolentAI’s artificial intelligence and machine learning capabilities the company aims to remain as f... lexible as possible should sufficiently interesting opportunities present themselves in the future. Other potential applications of the company’s technology could see the team move into other areas of biomedical discovery particularly relating to women’s health, rare human diseases, veterinary medicine, nutraceuticals, cosmeceuticals and agri-tech.
BENEVOLENTBIO
Industry:
Artificial Intelligence (AI) Biotechnology Machine Learning Nutraceutical
Founded:
2013-01-01
Address:
Brooklyn, New York, United States
Country:
United States
Website Url:
http://www.benevolent.ai
Total Employee:
251+
Status:
Closed
Technology used in webpage:
Domain Not Resolving SPF IPv6 Cloudflare Hosting Google Google Cloud Google Apps For Business Microsoft Azure DNS Cloudflare DNS Hubspot Forms
Official Site Inspections
http://www.benevolent.ai
- Host name: 104.21.36.136
- IP address: 104.21.36.136
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BenevolentBio"
BenevolentAI unveils strategic plan to position the …
May 25, 2023 BenevolentAI (AMS: BAI) is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery. Through the …See details»
BenevolentAI - Crunchbase Company Profile & Funding
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock …See details»
BenevolentAI - LinkedIn
BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development. In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack ...See details»
BenevolentAI unveils major strategic overhaul with …
Dec 11, 2024 BenevolentAI (“the Company”), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding TechBio mission. These …See details»
Benevolent.ai - VentureRadar
"BenevolentAI creates and applies AI technologies to transform the way medicines are discovered and developed. BenevolentAI seeks to improve patients’ lives by applying technology …See details»
BenevolentAI - The Org
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our …See details»
BenevolentAI - Funding, Financials, Valuation & Investors
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. ... How much …See details»
Mulvany hits the reset button at BenevolentAI
5 days ago "AI-driven drug discovery, a field that was once revolutionary, is now a fundamental expectation for modern R&D organisations," said Mulvany, who was named executive chairman of BenevolentAI a few ...See details»
BenevolentAI - Craft
Oct 29, 2024 BenevolentAI is a clinical-stage AI-enabled drug discovery company. It offers a Benevolent Platform that features clinical sub-typing, biomarker assessment, experimental …See details»
BenevolentAI exploring novel AI-driven drug discovery …
May 3, 2023 “Our approach at Benevolent is to use AI and machine learning to interrogate the vast amounts of genomic, transcriptomic and proteomic data,” Phelan explained. Phelan emphasized the importance of integrating different …See details»
BenevolentAI is about to disrupt pharma in a big way | WIRED
Aug 31, 2017 Benevolent AI can also use the predictive power of its AI algorithm to design new molecules, extracting new hypothesis based on a knowledge graph composed of over a billion …See details»
BenevolentAI - Contacts, Employees, Board Members, Advisors
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company.See details»
How BenevolentAI bounced back from a $1 billion loss | WIRED
May 5, 2020 Benevolent AI saw half its value wiped away in one fell swoop last year, when the fund of major backer Neil Woodford collapsed. Here’s what it did nextSee details»
What is BenevolentAI? - Open AI Master
Sep 14, 2023 BenevolentAI is on a mission to change the face of drug discovery by leveraging cutting-edge artificial intelligence. Their vision is crystal clear: to harness the power of …See details»
BenevolentAI secures $2bn valuation after raising $115mn in funding
May 17, 2020 BenevolentAI is working to use AI as a way of discovering new medicines and treatments for difficult and stubborn diseases. Within the pharmaceutical industry, Benevolent …See details»
BenevolentAI | World Economic Forum
Aug 5, 2020 The World Economic Forum is an independent international organization committed to improving the state of the world by engaging business, political, academic and other leaders …See details»
BenevolentAI Unveils Strategic Plan to Position the Company for a …
May 25, 2023 Enquiries: [email protected] [email protected] T: +44(0) 203 781 9360 FTI Consulting – Media enquiries: Ben Atwell/Dwight Burden/Victoria Foster Mitchell/Julia …See details»
BenevolentAI - AI-Powered Drug Discovery and Development
Features Benevolent Platform™: A versatile, scalable, and robust AI-enabled drug discovery platform. Multi-modal Data Foundations: Leverages diverse data sources for comprehensive …See details»
OpenAI announces nonprofit commission advisors | OpenAI
Apr 15, 2025 This commitment reflects OpenAI’s broader goal of unlocking unprecedented scale and impact for nonprofit organizations. By harnessing AI’s transformational power, nonprofits …See details»
OpenAI dials back conversion plan, nonprofit to retain control
11 hours ago OpenAI has dialed back a significant restructuring plan, with its nonprofit parent retaining control in a move that is likely to limit CEO Sam Altman's power over the pioneering …See details»